Robert A. Kloner MD, PhD, is the Interim Chief Science Officer, Director of the Cardiovascular Research Institute, and Vice President of Translation at HMRI. He is Professor of Medicine (Clinical Scholar) at the Keck School of Medicine at University of Southern California in Los Angeles. He is also an attending cardiologist at LAC/USC.
Dr. Kloner’s group is currently studying novel therapies to treat hemorrhagic shock, new agents to reduce microvascular abnormalities following a heart attack, and therapies that reduce the amount of damage that occurs during a heart attack. Dr. Wangde Dai serves as the head of cardiovascular surgery and Dr. Jianru Shi runs molecular cardiology. Sharon Hale works on data analysis, manuscript and grant preparation. The cardiovascular group is examining agents that protect the mitochondria (energy producing factories of cells) from injury in experimental heart attack and heart failure models. They are also investigating the benefits of therapeutic hypothermia on microvascular perfusion, cardiac structure, function and gene expression. They are developing collaborations with other HMRI scientists including the neuroscientist groups (Dr. Harrington) to better understand how cardiovascular disease may interact with dementia, as well as with the imaging group (Dr. King) to assess the brain-heart and vascular connection, and Dr. Pahlevan to help develop a noninvasive smart phone application to monitor heart failure patients. Dr. Kloner moved the Journal of Cardiovascular Pharmacology and Therapeutics to HMRI in 2015 where he continues to serve as Editor-in-Chief. Sharon Hale serves as Assistant Editor.